The Banc de Sang i Teixits (BST) and the Sant Pau Research Institute (IR Sant Pau), both members of CataloniaBio & HealthTech, signed a collaboration agreement aimed at promoting the development and production of innovative drugs. The agreement, which represents a pioneering alliance between two leading institutions in the health field, establishes the foundations for the creation of a joint hub that will have facilities prepared to produce advanced therapies, including CAR-T cells.
Within the framework of this agreement, the IR Sant Pau commits to involve the Banc de Sang i Teixits (BST) in the production of its CAR-T in clinical trials, consolidating them as an alternative facility for these advanced therapies.
With this collaboration, the technical knowledge of the BST merges with the research experience of the Sant Pau Institute, enhancing the capacity for innovation in the field of advanced therapies.
One of the main functions of the Banc de Sang i Teixits (BST) is to provide research teams worldwide with professional experience and manufacturing capacity for advanced therapy drugs, leveraging the knowledge gained from unique facilities in the country, with 10 clean rooms and a leading track record in technological advancements dedicated to serving these types of therapies for years.
The main headquarters of the BST has the necessary laboratory, equipment, and technology, especially cryopreservation tanks, to maintain these advanced therapy drugs, and above all, experts capable of handling these products. A network model of experience that has been a pioneer in implementing innovative cancer therapies throughout the public hospital network.
The general director of the Banc de Sang i Teixits, Anna Millan Álvarez, emphasizes that the signed agreement is the consolidation of a collaborative relationship between both institutions for many years, and thanks to which "we have achieved goals in the field of research that help position the Catalan innovation ecosystem in health and advanced therapies at the forefront."
The director of IR Sant Pau, Jordi Surrallés, has highlighted the importance of this alliance. "This agreement represents a unique opportunity to advance in the field of personalized medicine and advanced therapies. We are convinced that, together, we will achieve important goals to promote research and improve the health and well-being of patients."
Comments